Worldwide obesity has been nearly doubled since 1980. However, anti-obesity medications that have been developed so far have limited ef ficacies and considerable side ef fects. To solve this problem, we focused on the vascular endothelial cells in adipose tissue as a new therapeutic target, since the blood vessels play a crucial role for adipose tissue development and hyper trophy. Thus, we attempted to develop a novel platform for drug deliver y based on the active targeting, and succeeded in in vivo obesity treatment via the Prohibitin-Targeted Nano Par ticle (PTNP) modified with the high af finity peptide (KGGRAKD) to prohibitin expressed on the sur face of vascular endothelial cells in adipose tissue. In addition, we found that the accumulation of long circulating nanopar ticles into adipose tissue was passively enhanced by the enhanced permeability and retention (EPR) ef fect, when they were administered to obese animals. On the basis of these results, we firstly proposed the strategy of adipose vasculature targeted nanotherapy for obesity treatment.

